Abstract:Introduction: Hypoxic persistent pulmonary hypertension in the newborn (PPHN) is usually treated with oxygen and inhaled nitric oxide (NO), both pulmonary arterial relaxants. But treatment failure with NO occurs in 25% of cases. We previously demonstrated that 72 h exposure to hypoxia, modeling PPHN, sensitized pulmonary artery smooth muscle cells (PASMC) to the contractile agonist thromboxane and inhibited relaxant adenylyl cyclase (AC) activity. Methods: In this study, we examined the effects of sodium nitroprusside (SNP), as NO donor, on the thromboxane-mediated contraction and NO-independent relaxation pathways and on reactive oxygen species (ROS) accumulation in PASMC. In addition, we examined the effect of the peroxynitrite scavenger 5,10,15,20-Tetrakis (4-sulfonatophenyl)porphyrinato Iron (III) (FeTPPS) on these processes. Results: Exposure of PASMC to 72 h hypoxia increased total intracellular ROS compared to normoxic control cells and this was mitigated by treatment of cells with either SNP or FeTPPS. Total protein nitrosylation was increased in hypoxic PASMC compared to controls. Both normoxic and hypoxic cells treated with SNP exhibited increased total protein nitrosylation and intracellular nitrite; this was reduced by treatment with FeTPPS. While cell viability and mitochondrial number were unchanged by hypoxia, mitochondrial activity was decreased compared to controls; addition of FeTPPS did not alter this. Basal and maximal mitochondrial metabolism and ATP turnover were reduced in hypoxic PASMC compared to controls. Hypoxic PASMC had higher basal Ca2+, and a heightened peak Ca2+ response to thromboxane challenge compared to controls. Addition of SNP further elevated the peak Ca2+ response, while addition of FeTPPS brought peak Ca2+ response down to control levels. AC mediated relaxation was impaired in hypoxic PASMC compared to controls but was normalized following treatment with FeTPPS. Addition of SNP inhibited adenylyl cyclase activity in both normoxic and hypoxic PASMC. Moreover, addition of the Ca2+ chelator BAPTA improved AC activity, but the effect was minimal. Discussion: We conclude that NO independently augments contraction and inhibits relaxation pathways in hypoxic PASMC, in part by a mechanism involving nitrogen radical formation and protein nitrosylation. These observations may partially explain impaired effectiveness of NO when treating hypoxic pulmonary hypertension.

NADPH Oxidase: Its Potential Role in Promotion of Pulmonary Arterial Hypertension.

Nadph Oxidase Activation Played A Critical Role in the Oxidative Stress Process in Stable Coronary Artery Disease

Suppression of NADPH Oxidase Attenuates Hypoxia-Induced Dysfunctions of Endothelial Progenitor Cells.

Coordination Between NADPH Oxidase and Vascular Peroxidase 1 Promotes Dysfunctions of Endothelial Progenitor Cells in Hypoxia-Induced Pulmonary Hypertensive Rats.

NADPH Oxidases and Respiratory Diseases

NADPH oxidases and oxidase crosstalk in cardiovascular diseases: novel therapeutic targets

The Role of NOX4 in Pulmonary Diseases

[Research Progress in NADPH Oxidase Family in Cardiovascular Diseases].

NOX4 Expression and Distal Arteriolar Remodeling Correlate with Pulmonary Hypertension in COPD

Oxidative Stress and Antioxidative Therapy in Pulmonary Arterial Hypertension

The expression and function of NADPH oxidase in common cardiovascu-lar diseases

NADPH oxidase family proteins: signaling dynamics to disease management

Dysfunctional endothelial progenitor cells in cardiovascular diseases: role of NADPH oxidase.

NADPH oxidases: an overview from structure to innate immunity-associated pathologies

Vascular peroxidase 1 mediates hypoxia-induced pulmonary artery smooth muscle cell proliferation, apoptosis resistance and migration

Unique Role of NADPH Oxidase 5 in Oxidative Stress in Human Renal Proximal Tubule Cells.

Diabetic retinopathy: Focus on NADPH oxidase and its potential as therapeutic target

Nitric oxide augments signaling for contraction in hypoxic pulmonary arterial smooth muscle—Implications for hypoxic pulmonary hypertension

Therapy for Pulmonary Arterial Hypertension: Glance on Nitric Oxide Pathway

NADPH Oxidase Inhibition in Fibrotic Pathologies

Effects of Pharmacological Inhibitors of NADPH Oxidase on Myogenic Contractility and Evoked Vasoactive Responses in Rat Resistance Arteries